MyoKardia initiated with an Overweight at Morgan Stanley

MyoKardia initiated with an Overweight at Morgan Stanley. Morgan Stanley analyst Jeffrey Hung initiated (MYOK) at Overweight with a $72 price target, stating that the obstructive hypertrophic cardiomyopathy Phase 2 data for its lead program, mavacamten, were “robust” and the fact that the company is partnered with Sanofi (SNY) gives him incremental confidence. He expects a mavacamten launch in oHCM in early 2022 and peak U.S. sales for the drug of greater than $1.3B.
https://thefly.com/landingPageNews.php?id=2787817